Biolexis News.

Biolexis Therapeutics Completes Promising Pre-Clinical Studies on Novel Isoform-Specific AMPK Agonists for Weight Loss Treatment

Read more

Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies

Read more

Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

Read more
The work has begun. Join us.
JOIN US